Raymond James Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Raymond James Financial’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,721	Closed	-$227K	–	7075
2025 Q1	$227K	Sell	1,721 -913,640	-100%	-$114M	﹤0.01%	4353
2024 Q4	$76.5M	Buy	+915,361	New	+$75.2M	0.03%	518

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Raymond James Financial's ITCI Position: Q2 2025 in Review

Raymond James Financial sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,721 shares — an estimated $227K sold.

Raymond James Financial first reported a position in ITCI in Q4 2024 and held it in 2 quarters. The position peaked at $76.5M in Q4 2024. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Raymond James Financial reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Raymond James Financial sold 1,721 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $227K.
Raymond James Financial first reported a position in Intra-Cellular Therapies Inc. in Q4 2024 and held it in 2 quarters.
Raymond James Financial's Intra-Cellular Therapies Inc. position peaked at $76.5M in Q4 2024.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Raymond James Financial's 13F filing for Q2 2025, filed 14 Aug 2025.